Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1499 • ACR Convergence 2021
Imbalance Between T Follicular Cells and T Regulatory Cells Involved in High Fat-Diet Associated Lupus Development in MRL/lpr Mice
Ronak Patel¹, Therese Posas-Mendoza², Juan Meng³, Xuhua Shi³, Swathi Dhulipala⁴, Chad Hille², Linh Hellmers¹, Robert Quinet⁵, William Davis⁶, Jerald Zakem⁷, Chandana Keshavamurthy¹, Zongbing You³ and Xin Zhang¹, ¹Ochsner, New Orleans, LA, ²Ochsner Clinic Foundation, New Orleans, LA, ³Tulane University, New Orleans, LA, ⁴Ochsner Clinic Foundation, River Ridge, LA, ⁵Ochsner Health, River Ridge, LA, ⁶Ochsner Medical Center, New Orleans, LA, ⁷Ochsner Health Systems, Metairie, LA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by persistent inflammation and production of autoantibodies, which deposit within numerous tissues leading to…
Abstract Number: 1637 • ACR Convergence 2021
Covid-19 Infection Among Pediatric Rheumatology Patients: A Single Center Experience
Eric Kok, Martha Curry, Andrea Ramirez, Eyal Muscal and Marietta DeGuzman, Baylor College of Medicine, Houston, TX
Background/Purpose: Infection with novel coronavirus (COVID-19) in children, unlike adults, is generally asymptomatic or causes mild disease although some may develop severe illness. In particular,…
Abstract Number: 1740 • ACR Convergence 2021
Efficacy of Anifrolumab in Patients with SLE Previously Treated with Biologics: Post Hoc Analysis of Data from 2 Phase 3 Trials
Richard Furie¹, Eric Morand², Kenneth Kalunian³, Konstantina Psachoulia⁴, Emmanuelle Maho⁵, Catharina Lindholm⁶ and Raj Tummala⁴, ¹Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ²Monash University, Melbourne, Australia, ³University of California, La Jolla, CA, ⁴BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁶BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background/Purpose: In the phase 3 TULIP-1 and TULIP-2 trials, anifrolumab, a type I IFN receptor mAb, improved disease activity in patients with SLE.1,2 We investigated…
Abstract Number: 1758 • ACR Convergence 2021
WITHDRAWN
Abstract Number: 1909 • ACR Convergence 2021
Impact of Antimalarial Adherence on Cardiovascular Mortality Among Patients with Newly Diagnosed Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population-based Study
Md Rashedul Hoque¹, J. Antonio Avina-Zubieta², Diane Lacaille², Mary De Vera³, Yi Qian³, John Esdaile⁴ and Hui Xie⁵, ¹Simon Fraser University, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵Simon Fraser University, Burnaby, BC, Canada
Background/Purpose: Literature has shown poor adherence to antimalarial (AM) medications in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients, with the percentage of adherers…
Abstract Number: 0164 • ACR Convergence 2021
Disrupted Executive Control Network Structural-Functional Integration Is Associated with Inferior Performance of Cognitive Switching Tasks in Patients with Systemic Lupus Erythematosus (SLE)
Xing Qian¹, Danielle S Bassett², Kwun Kei Ng¹, Beatrice RY Loo¹, Amelia J Koh¹, Juan Helen Zhou¹ and Anselm Mak³, ¹Center for Sleep and Cognition, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ²Departments of Physics & Astronomy, Bioengineering, Electrical & Systems Engineering, Neurology, and Psychiatry, University of Pennsylvania, Philadelphia, PA, ³National University of Singapore, Singapore, Singapore
Background/Purpose: Cognitive flexibility, a process that enables goal-oriented cognitive switching between mental function modes, is central to executive function which is impaired in SLE patients.…
Abstract Number: 0335 • ACR Convergence 2021
Performances of Different Classification Criteria for Systemic Lupus Erythematosus in a Single Center Cohort from Turkey
Ege Sinan Torun¹, Erdem Bektaş¹, Fatih Kemik², Murat Bektaş³, Cigdem Cetin⁴, Yasemin Yalcinkaya⁴, Bahar Esen⁴, Ahmet Gül⁵ and Murat Inanc⁶, ¹Istanbul University Istanbul Faculty of Medicine, İstanbul, Turkey, ²Istanbul Faculty of Medicine, Istanbul University, Department of Internal Medicine, İstanbul, Turkey, ³Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ⁵Division of Rheumatology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey, ⁶Istanbul University Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Recently developed EULAR/ACR classification criteria for systemic lupus erythematosus (SLE) has important differences compared to the 2012 Systemic Lupus International Collaborating Clinics (SLICC) SLE…
Abstract Number: 0354 • ACR Convergence 2021
A Cross-Sectional Study of Rheumatoid Arthritis Diagnoses in Patients with Systemic Lupus Erythematosus
Kathryn Starzyk¹, Gary Curhan² and Julia Brault², ¹OM1, Inc, Boston, MA, ²OM1, Boston, MA
Background/Purpose: Features of autoimmune conditions may coexist in individual patients, which may represent an overlapping single disease with features of both (i.e., ‘rhupus’), or the…
Abstract Number: 0537 • ACR Convergence 2021
The Clinical, Oral Small Molecule IRAK4 Inhibitor, GS-5718, Improves Survival and Reduces Disease Pathologies by Modulating Multiple Inflammatory Endpoints in the Murine NZB/W Model of Spontaneous Lupus
Adam Yadon¹, Vanessa Gorney², Angie Hammond³, Ethan Grant² and Astrid Clarke³, ¹Gilead Sciences, Inc., Seattle, WA, ²Gilead Sciences, Inc, Foster City, CA, ³Gilead Sciences, Inc, Seattle, WA
Background/Purpose: Lupus is a heterogenous autoimmune disease characterized by loss of immune tolerance, production of nucleic acid:autoantibody immune complexes, immune cell hyperactivation, and increased proinflammatory…
Abstract Number: 0628 • ACR Convergence 2021
Higher Quality of Care for Patients with Systemic Lupus Erythematosus in a Subspecialty Lupus Clinic: A Multi-Setting Cross-Sectional Study
Sidha Sreedharan¹, Ning Li¹, Geoffrey Littlejohn¹, Russell Buchanan², Mandana Nikpour³, Eric Morand⁴, Alberta Hoi⁵ and Vera Golder⁶, ¹Monash University, Melbourne, Australia, ²Austin Health, Heidelberg, Melbourne, Australia, ³University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ⁴School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia, ⁵Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia, ⁶Monash University, Clayton, Australia
Background/Purpose: Healthcare quality for systemic lupus erythematosus (SLE) is a modifiable target for improving patient outcomes. Disease-specific subspecialty lupus clinics may offer experienced healthcare professionals,…
Abstract Number: 0859 • ACR Convergence 2021
Evaluation of the Montreal Cognitive Assessment as a Screening Tool for Cognitive Dysfunction in Systemic Lupus Erythematosus
Sudha Raghunath¹, Yifat Glikmann-Johnston¹, Eric Morand², Julie Stout¹ and Alberta Hoi³, ¹Monash University, Melbourne, Australia, ²School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia, ³Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia
Background/Purpose: Cognitive dysfunction (CD) affects approximately 40% of SLE patients (1), impacting on employment, daily function, and quality of life (2)(3). Diagnostic neuropsychological testing is…
Abstract Number: 0876 • ACR Convergence 2021
Antibody Response in Patients with Systemic Lupus Erythematosus After a Two-dose Regimen with SARS-CoV-2 Vaccines (Preliminary Results)
Emilie Stavnsbjerg Larsen¹, Anna Christine Nilsson², Ulrik Stenz Justesen¹, Anne Voss³ and Isik Somuncu Johansen⁴, ¹Odense University Hospital, Odense C, Denmark, ²Odense Universitets Hospital, Odense C, Denmark, ³Department of Rheumatology, Odense University Hospital, Odense C, Denmark, ⁴Odense University Hospital, Odense, Denmark
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) often receive immunosuppressive treatment for many years, resulting in higher risk of infections, including COVID-19, and infections may…
Abstract Number: 0894 • ACR Convergence 2021
Help-seeking Behaviors and Treatment Preferences for Sleep Problems Among Persons with Lupus
Deborah Da Costa¹, Josée Savard², Elham Rahme¹ and Paul R Fortin³, ¹McGill University, Montréal, QC, Canada, ²Université Laval, Québec City, QC, Canada, ³CHU de Quebec - Universite Laval, Québec City, QC, Canada
Background/Purpose: Sleep disturbances, including difficulty initiating sleep, maintaining sleep, and/or early morning awakenings are prevalent among persons with lupus and have been shown to contribute…
Abstract Number: 1042 • ACR Convergence 2021
Multimorbidity Prevalence in Systemic Lupus Erythematosus: A Population-Based Study
Ali Duarte-Garcia¹, Maria Valenzuela-Almada², Mehmet Hocaoglu³, Jesse Dabit¹, Shirley-Ann Osei-Onomah¹, Sebastian Vallejo-Ramos¹, Kurt Greenlund⁴, Tina Gunderson¹, Kamil Barbour⁴ and Cynthia Crowson⁵, ¹Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Mayo Clinic, Rochester, MN, ³University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ⁴Centers for Disease Control, Atlanta, GA, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a 3-fold increase in all-cause mortality, compared to the general population. Young patients with SLE are 40…
Abstract Number: 1257 • ACR Convergence 2021
Improvements in Abnormal Laboratory Tests Are Associated with Clinical Outcomes in Patients with Active Systemic Lupus Erythematosus
Kathryn Connelly¹, Rangi Kandane-Rathnayake¹, Alberta Hoi², Worawit Louthrenoo³, Laniyati Hamijoyo⁴, Jiacai Cho⁵, Aisha Lateef⁶, Shue-Fen Luo⁷, Yeong-Jian Wu⁸, Zhanguo Li⁹, Yuan An⁹, Sandra Navarra¹⁰, Leonid Zamora¹⁰, Sargunan Sockalingam¹¹, Yanjie Hao¹², Zhuoli Zhang¹², Yasuhiro Katsumata¹³, Masayoshi Harigai¹³, Shereen Oon¹⁴, Madelynn Chan¹⁵, YI-HSING CHEN¹⁶, Sang-Cheol Bae¹⁷, Sean O’Neill¹⁸, Kathryn Gibson¹⁸, Fiona Goldblatt¹⁹, Jun Kikuchi²⁰, Tsutomu Takeuchi²¹, Kristine (Pek Ling) Ng²², Nicola Tugnet²³, B.M.D.B. Basnayake²⁴, Yoshiya Tanaka²⁵, C.S. Lau²⁶, Mandana Nikpour²⁷, Vera Golder¹ and Eric Morand²⁸, ¹Monash University, Clayton, Australia, ²Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia, ³Maharaj Nakorn Chiangmai, Chiang Mai, Thailand, ⁴University of Padjadjaran, Bandung, Indonesia, ⁵National University Health System (NUHS), Singapore, Singapore, ⁶National University Hospital, Singapore, Singapore, ⁷Chang Gung Memorial Hospital, Taipei, Taiwan, ⁸Chang Gung Memorial Hospital, Taoyuan County, Taiwan, ⁹People's Hospital, Peking University Health Science Center, Beijing, China (People's Republic), ¹⁰University of Santo Tomas Hospital, Manila, Philippines, ¹¹University of Malaya, Kuala Lumpur, Malaysia, ¹²Peking University First Hospital, Beijing, China (People's Republic), ¹³Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ¹⁴Melbourne Health, Parkville, Australia, ¹⁵Tan Tock Seng Hospital, Singapore, Singapore, ¹⁶Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ¹⁷Hanyang University Medical Center, Seoul, Republic of Korea, ¹⁸Liverpool Hospital, Sydney, Australia, ¹⁹Flinders Medical Centre, Adelaide, Australia, ²⁰Keio University School of Medicine, Tokyo, Japan, ²¹Div. Rheumatology, Keio University, Tokyo, Japan, ²²North Shore Hospital, Auckland, New Zealand, ²³Auckland District Health Board, Auckland, New Zealand, ²⁴Teaching (General) Hospital, Kandy, Sri Lanka, ²⁵University of Occupational and Environmental Health, Kitakyushu, Japan, ²⁶University of Hong Kong, Hong Kong, Hong Kong, ²⁷University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ²⁸School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia
Background/Purpose: Laboratory tests are routine in the management of SLE. In clinical trial endpoints, data from laboratory tests contribute to responder status, but this is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].